MA41060B1 - Compositions comprenant des souches bactériennes - Google Patents

Compositions comprenant des souches bactériennes

Info

Publication number
MA41060B1
MA41060B1 MA41060A MA41060A MA41060B1 MA 41060 B1 MA41060 B1 MA 41060B1 MA 41060 A MA41060 A MA 41060A MA 41060 A MA41060 A MA 41060A MA 41060 B1 MA41060 B1 MA 41060B1
Authority
MA
Morocco
Prior art keywords
compositions
bacterial strains
inflammatory
prevention
treatment
Prior art date
Application number
MA41060A
Other languages
English (en)
Other versions
MA41060A (fr
Inventor
George Grant
Angela Margaret Patterson
Imke Mulder
Seanin Mccluskey
Emma Raftis
Original Assignee
4D Pharma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1510469.8A external-priority patent/GB201510469D0/en
Priority claimed from GBGB1520628.7A external-priority patent/GB201520628D0/en
Priority claimed from GBGB1604566.8A external-priority patent/GB201604566D0/en
Application filed by 4D Pharma Res Ltd filed Critical 4D Pharma Res Ltd
Publication of MA41060A publication Critical patent/MA41060A/fr
Publication of MA41060B1 publication Critical patent/MA41060B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

L'invention concerne des compositions comprenant des souches bactériennes pour le traitement et la prévention de maladies inflammatoires et auto-immunes.
MA41060A 2015-06-15 2016-06-14 Compositions comprenant des souches bactériennes MA41060B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1510469.8A GB201510469D0 (en) 2015-06-15 2015-06-15 Compostions comprising bacterial strains
GBGB1520628.7A GB201520628D0 (en) 2015-11-23 2015-11-23 Compositions comprising bacterial strains
GBGB1604566.8A GB201604566D0 (en) 2016-03-17 2016-03-17 Compositions comprising bacterial strains
PCT/GB2016/051773 WO2016203220A1 (fr) 2015-06-15 2016-06-15 Compositions comprenant des souches bactériennes

Publications (2)

Publication Number Publication Date
MA41060A MA41060A (fr) 2017-08-15
MA41060B1 true MA41060B1 (fr) 2019-11-29

Family

ID=56194512

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41060A MA41060B1 (fr) 2015-06-15 2016-06-14 Compositions comprenant des souches bactériennes

Country Status (31)

Country Link
US (4) US10493112B2 (fr)
EP (4) EP3369425B1 (fr)
JP (2) JP6389950B2 (fr)
KR (1) KR20180012845A (fr)
CN (2) CN108738311B (fr)
AU (2) AU2016278069B2 (fr)
BR (1) BR112017025003A2 (fr)
CA (2) CA2988686C (fr)
CL (1) CL2017003191A1 (fr)
CO (1) CO2017013231A2 (fr)
CY (3) CY1122467T1 (fr)
DK (3) DK3549592T3 (fr)
EA (1) EA201890049A1 (fr)
ES (3) ES2863913T3 (fr)
HR (3) HRP20192057T1 (fr)
HU (3) HUE052737T2 (fr)
IL (1) IL255783B2 (fr)
LT (3) LT3549592T (fr)
MA (1) MA41060B1 (fr)
MD (3) MD3369425T2 (fr)
ME (2) ME03784B (fr)
MX (1) MX2017016564A (fr)
PE (1) PE20180266A1 (fr)
PL (3) PL3549592T3 (fr)
PT (3) PT3204025T (fr)
RS (3) RS59558B1 (fr)
SG (2) SG10201912322PA (fr)
SI (3) SI3369425T1 (fr)
TW (2) TWI782682B (fr)
WO (1) WO2016203220A1 (fr)
ZA (1) ZA201707774B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
SI3065748T1 (en) 2014-12-23 2018-05-31 4D Pharma Research Limited Severe bacteroid tethethioomycron and its use in reducing inflammation
WO2016102951A1 (fr) 2014-12-23 2016-06-30 4D Pharma Research Limited Polypeptide pirin et modulation immunitaire
EA201890050A1 (ru) 2015-06-15 2018-06-29 4Д Фарма Рисёрч Лимитед Композиции, содержащие бактериальные штаммы
MX2017016560A (es) 2015-06-15 2018-02-21 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas.
TWI797058B (zh) 2015-06-15 2023-04-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MD3209310T2 (ro) 2015-11-20 2018-06-30 4D Pharma Res Ltd Compoziții care conțin tulpini bacteriene
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
TW201733601A (zh) 2016-03-04 2017-10-01 ４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CA3211208A1 (fr) 2017-04-03 2018-10-11 Gusto Global, Llc Conception rationnelle d'agents biotherapeutiques d'origine microbienne
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
WO2018215782A1 (fr) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprenant des souches bactériennes
SI3638271T1 (sl) 2017-06-14 2021-01-29 4D Pharma Research Limited Sestavki, ki vsebujejo bakterijske seve
AU2018285445B2 (en) * 2017-06-14 2020-03-26 Cj Bioscience, Inc. Compositions comprising bacterial strains
GB201806779D0 (en) * 2018-04-25 2018-06-06 4D Pharma Res Ltd Compositions comprising bacterial strains
AU2018283994B2 (en) 2017-06-14 2021-03-18 4D Pharma Research Limited Compositions comprising bacterial strains
MX2020012061A (es) 2018-05-11 2022-10-13 4D Pharma Res Limited Composiciones que comprenden cepas bacterianas.
TWI688394B (zh) * 2018-09-04 2020-03-21 星聚樊生物科技有限公司 戈氏副擬桿菌用於預防或治療慢性阻塞性肺病之用途
TWI721549B (zh) * 2018-09-04 2021-03-11 星聚樊生物科技有限公司 戈氏副擬桿菌用於治療慢性腎臟疾病之用途
CN110917219B (zh) * 2018-09-04 2021-09-07 星聚樊生物科技有限公司 戈氏副拟杆菌用于制备预防和/或治疗慢性阻塞性肺病的医药组成物的用途
US20220047647A1 (en) * 2018-09-10 2022-02-17 Riken Composition for inhibiting trypsin activity containing as active ingredient bacterium belonging to genus paraprevotella
WO2020055193A1 (fr) * 2018-09-14 2020-03-19 Industry-Academic Cooperation Foundation, Yonsei University Micro-organisme à activité antibactérienne pour des bactéries pathogènes entériques et composition pharmaceutique pour la prévention et le traitement d'une maladie induite par des bactéries pathogènes entériques utilisant celui-ci
CA3113448A1 (fr) * 2018-09-27 2020-04-02 Research Development Foundation Methodes et compositions probiotiques destinees au traitement de lesions osseuses
US11116803B2 (en) * 2018-10-31 2021-09-14 Multistars Biotechnology Company Limited Method of treating lung cancer using Parabacteroides goldsteinii
MA54074A (fr) * 2018-11-02 2022-02-09 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2020120717A1 (fr) 2018-12-12 2020-06-18 4D Pharma Research Limited Compositions comprenant des souches bactériennes parabacteroides pour le traitement du cancer
CN110172427A (zh) * 2019-06-11 2019-08-27 江南大学 一种提高狄氏副拟杆菌冻干存活率的方法及应用
WO2021221110A1 (fr) * 2020-04-29 2021-11-04 学校法人慶應義塾 Petite bactérie intestinale induisant la prolifération ou l'activation de cellules th1 et/ou de cellules th17
CN112410242A (zh) * 2020-08-25 2021-02-26 上海市第十人民医院 一株分离自直肠癌肿瘤组织的狄氏副拟杆菌株及其应用
EP3967314A1 (fr) * 2020-09-15 2022-03-16 Institut national de recherche pour l'agriculture l'alimentation et l'environnement Souches de distasonis parabacteroides à utiliser dans le traitement et la prévention des maladies gastro-intestinales et de troubles associés à des maladies gastro-intestinales
CN114908022A (zh) * 2022-06-17 2022-08-16 中国海洋大学 一种副拟杆菌属菌株及其培养方法和应用

Family Cites Families (361)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
NL8300698A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
CA1333564C (fr) 1988-08-02 1994-12-20 Thomas Julius Borody Traitement des troubles gastro-intestinaux
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
KR100225087B1 (ko) 1990-03-23 1999-10-15 한스 발터라벤 피타아제의 식물내 발현
JP3110452B2 (ja) 1990-05-09 2000-11-20 ノボ ノルディスク アクティーゼルスカブ エンドグルカナーゼ酵素を含んでなるセルラーゼ調製物
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5443951A (en) 1992-07-20 1995-08-22 Kabushiki Kaisha Yakult Honsha Species-specific oligonucleotides for bifidobacteria and a method of detection using the same
ATE219143T1 (de) 1992-12-10 2002-06-15 Dsm Nv Herstellung von heterologen proteinen in filamentösen fungi
US5741665A (en) 1994-05-10 1998-04-21 University Of Hawaii Light-regulated promoters for production of heterologous proteins in filamentous fungi
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM823094A0 (en) 1994-09-16 1994-10-13 Goodman Fielder Limited Probiotic compositions
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
RU2078815C1 (ru) 1995-01-17 1997-05-10 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Штамм бактерий bifidobacterium breve, используемый для получения бактерийных лечебно-профилактических бифидосодержащих препаратов
JPH08259450A (ja) 1995-03-17 1996-10-08 Nichinichi Seiyaku Kk インターフェロン産生増強剤
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
AUPN698495A0 (en) 1995-12-06 1996-01-04 Pharma Pacific Pty Ltd Improved therapeutic formulation and method
SE508045C2 (sv) 1996-02-26 1998-08-17 Arla Ekonomisk Foerening Adhesionsinhibitorer, preparat innehållande desamma och förfarande för framställning därav
ATE407700T1 (de) 1996-03-20 2008-09-15 Univ New South Wales Veränderung der mikrobenflora im verdauungstrakt
AUPN881396A0 (en) 1996-03-20 1996-04-18 Arnott's Biscuits Limited Enhancement of microbial colonization of the gastrointestinal tract
ATE317005T1 (de) 1996-03-27 2006-02-15 Novozymes As Alkaline-phosphatase-defiziente, filamentöse pilze
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
WO1998043081A1 (fr) 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Traitement de troubles gastro-intestinaux au moyen de modulateurs du recepteur active de la proliferation des peroxysomes (ppar)
SE511524C2 (sv) 1997-06-02 1999-10-11 Essum Ab Lactobacillus casei rhamnosus-stam samt farmaceutisk beredning för bekämpning av patogena tarmbakterier
US5925657A (en) 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
IT1298918B1 (it) 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
DE19826928A1 (de) 1998-06-17 1999-12-23 Novartis Consumer Health Gmbh Arzneimittel, lebensfähige anaerobe Bakterien enthaltend, die die Sulfatreduktion sulfatreduzierender Bakterien hemmen
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7090973B1 (en) 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
CA2382966A1 (fr) 1999-08-27 2001-03-08 Eli Lilly And Company Derives de biaryl-oxa(thia)zole et leur utilisation en tant que modulateurs de ppar
CN101238853A (zh) 2000-02-08 2008-08-13 Dsmip资产公司 酸-稳定性蛋白酶在动物饲料中的用途
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
JP2004536557A (ja) 2000-11-27 2004-12-09 ワシントン・ユニバーシティ 哺乳動物の腸に対する共生ミクロフローラの効果を調べるための方法およびそれに基づく胃腸関連疾患の治療
DE10101793A1 (de) 2001-01-17 2002-08-01 Manfred Nilius Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen
EP1227152A1 (fr) 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Souche bactérienne et genome de bifidobacterium
KR100437497B1 (ko) 2001-03-07 2004-06-25 주식회사 프로바이오닉 로타바이러스 및 유해 미생물 억제 활성을 가지는 신규내산성 락토바실러스 루테리 프로바이오-16 및 이를함유하는 생균활성제
EP1243273A1 (fr) 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition contenant un agent prebiotique pour le traitement d'inflammation et d'activation anormal des agents immunitaires non-spécifiques
DE60141773D1 (de) 2001-04-20 2010-05-20 Inst Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
EP1260227A1 (fr) 2001-05-23 2002-11-27 Societe Des Produits Nestle S.A. L'acide lipoteichoique des bacteries lactiques et son utilisation pour moduler des responses immunitaites induites par des bacteries a gram negatif, gram positif
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
CA2457092A1 (fr) 2001-09-05 2003-03-20 Vsl Pharmaceuticals, Inc. Utilisation de cytosine-guanine (cpg) non methylee
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
WO2003045317A2 (fr) 2001-11-27 2003-06-05 Washington University Proteine therapeutique et traitements
EP1581119B1 (fr) 2001-12-17 2013-01-30 Corixa Corporation Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
DE10206995B4 (de) 2002-02-19 2014-01-02 Orthomol Pharmazeutische Vertriebs Gmbh Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
JP2003261453A (ja) 2002-03-11 2003-09-16 Nippon Berumu Kk Ｅ．フェカリスからなる抗腫瘍剤及び放射線防護剤
NZ537706A (en) 2002-06-28 2008-03-28 Puleva Biotech Sa Probiotic microbial strains, comprising non-pathogenic strains which are capable of surviving in and being transferred to breast milk and/or amniotic fluid after oral intake in healthy individuals without colonizing other internal organs except mucousas
US20040005304A1 (en) 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
EP1481681A1 (fr) 2003-05-30 2004-12-01 Claudio De Simone Combinaisons de bactéries lactiques et leur compositions
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
AU2003247193A1 (en) 2003-07-23 2005-02-04 M.D.Lab Corp. Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus
US7485325B2 (en) 2003-08-06 2009-02-03 Gayle Dorothy Swain Animal food supplement compositions and methods of use
JP4683881B2 (ja) 2003-08-27 2011-05-18 有限会社アーク技研 抗腫瘍活性剤
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20050163764A1 (en) 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
GB0323039D0 (en) 2003-10-01 2003-11-05 Danisco Method
JP4740866B2 (ja) 2003-10-24 2011-08-03 ナムローゼ フェンノートシャップ ニュートリシア 乳児向けシンバイオティック組成物
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
CN100421676C (zh) 2003-12-17 2008-10-01 纽迪西亚公司 乳酸产生细菌和肺功能
ES2235642B2 (es) 2003-12-18 2006-03-01 Gat Formulation Gmbh Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
AU2005227320B2 (en) 2004-03-22 2010-06-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, National Insitutes Of Health Cellular and viral inactivation
JP2007535924A (ja) 2004-05-07 2007-12-13 − グスタフ ユングレン、ハンス ワクチン用アジュバントとしてのフラジェリンの使用
US7638513B2 (en) 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
CA2611377C (fr) 2004-06-07 2019-04-09 Harold David Gunn Compositions bacteriennes pour le traitement d'un cancer
EP1629850B2 (fr) 2004-08-24 2013-05-22 N.V. Nutricia Composition nutritive comprenant des transgalactooligosaccharides indigestibles et des galactose saccharides digestibles
US20060062742A1 (en) 2004-09-21 2006-03-23 The Procter & Gamble Company Compositions for reduction of human malodor
KR100468522B1 (ko) 2004-10-12 2005-01-31 주식회사 프로바이오닉 코로나바이러스와 돼지 써코바이러스 2형의 생육을 억제하는 신규한 내산성 프로바이오틱 엔테로코커스훼시움 프로바이오-63
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
ITMI20042189A1 (it) 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
TR201820329T4 (tr) 2005-02-28 2019-01-21 Nutricia Nv Probiyotik İçeren Besin Bileşimi
US20090233888A1 (en) 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
WO2006102350A1 (fr) 2005-03-23 2006-09-28 Washington University In St. Louis Utilisation d'archees pour moduler les fonctions de capture des nutriments par la microbiote gastro-intestinale
JP2006265212A (ja) 2005-03-25 2006-10-05 Institute Of Physical & Chemical Research Ｉｌ−２１産生誘導剤
US20100233312A9 (en) 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
EP1714660A1 (fr) 2005-04-21 2006-10-25 N.V. Nutricia D'acide uronique et des probiotiques
WO2006114778A1 (fr) 2005-04-26 2006-11-02 Teagasc- The Agriculture And Food Development Authority Composition probiotique convenant aux animaux
US7572474B2 (en) 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US8075934B2 (en) 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
JP2007084533A (ja) 2005-08-24 2007-04-05 Prima Meat Packers Ltd 免疫応答調節組成物及び該組成物を有効成分とする食品
US7625704B2 (en) 2005-08-31 2009-12-01 Fred Hutchinson Cancer Research Center Methods and compositions for identifying bacteria associated with bacteria vaginosis
DK1933869T3 (da) 2005-09-01 2010-03-01 Schering Corp Anvendelse af IL-23- og IL-17-antagonister til behandling af autoimmun øjenbetændelsessygdom
WO2007035057A1 (fr) 2005-09-23 2007-03-29 Gwangju Institute Of Science And Technology Composition pour la prevention ou le traitement d'arthrite comportant des bacteries lactiques et du collagene en tant que principes actifs
RU2411038C2 (ru) 2005-10-06 2011-02-10 Нестек С.А. Способ усиления эффективности вакцины и применение пробиотического штамма enterococcus faecium sf68 для усиления эффективности вакцины
EP1776877A1 (fr) 2005-10-21 2007-04-25 N.V. Nutricia Méthode de stimulation de la flore intestinale
EP1940243B1 (fr) 2005-10-24 2011-08-03 Nestec S.A. Preparation de fibres alimentaires et leur methode d'administration
JP2007116991A (ja) 2005-10-28 2007-05-17 Eternal Light General Institute Inc 機能性食品
US7767420B2 (en) 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
AU2006320604A1 (en) 2005-12-01 2007-06-07 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
US8889149B2 (en) 2006-02-16 2014-11-18 Wayne State University Use of flagellin to prevent and treat gram negative bacterial infection
US20080260906A1 (en) 2006-03-17 2008-10-23 Marko Stojanovic Compositions comprising probiotic and sweetener components
JP5031249B2 (ja) 2006-03-22 2012-09-19 学校法人北里研究所 炎症抑制作用のある菌体含有組成物
ES2688934T3 (es) 2006-03-29 2018-11-07 Nestec S.A. Suplementos alimentarios que contienen probióticos
CA2652559A1 (fr) 2006-05-18 2007-11-29 Biobalance Llc Compositions biotherapeutiques et utilisations connexes
CA2655665A1 (fr) 2006-05-26 2007-12-06 Nestec S.A. Procedes d'utilisation d'extrait de touchi et compositions nutritionnelles d'extrait de touchi associees
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EP2845496A1 (fr) 2006-08-04 2015-03-11 SHS International Ltd. Formule alimentaire sans protéine comprenant des prébiotiques
WO2008031438A2 (fr) 2006-09-13 2008-03-20 Region Hovedstaden V/Gentofte Hospital Traitement de l'asthme, de l'eczéma et / ou d'allergies à l'aide d'organismes non pathogènes
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
WO2008050209A1 (fr) 2006-10-27 2008-05-02 Pfizer Products Inc. Capsules dures en hydroxypropylméthylcellulose et leur procédé de fabrication
US20080118473A1 (en) 2006-11-01 2008-05-22 The Procter & Gamble Company Methods of treating a respiratory condition comprising probiotic treatment
EP1920781B1 (fr) 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprenant un microorganisme contenant core-1 et son utilisation pour le traitement des tumeurs
WO2008064489A1 (fr) 2006-12-01 2008-06-05 Mcmaster University Probiotiques destinés à inhiber les inflammations
WO2008076696A2 (fr) 2006-12-18 2008-06-26 Washington University In St. Louis Microbiome intestinal en tant que biomarqueur et cible thérapeutique pour traiter l'obésité ou un trouble lié à l'obésité
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
WO2008083157A2 (fr) 2006-12-29 2008-07-10 Washington University In St. Louis Altération du pgc-1alpha, de l'ampk, du fiaf, ou du microbiote gastro-intestinal comme moyen pour moduler les réserves lipidiques de l'organisme et/ou la perte de poids chez un sujet
JP2008195635A (ja) 2007-02-09 2008-08-28 Crossfield Bio Inc 馬用乳酸菌製剤
GB0703285D0 (en) * 2007-02-20 2007-03-28 Cutler Daniel Retractable covering apparatus
CN101678053B (zh) 2007-02-28 2015-12-16 Mjn美国控股有限责任公司 用于治疗或预防全身性炎症的方法
MY146590A (en) 2007-03-28 2012-08-30 Alimentary Health Ltd Probiotic bifidobacterium strains
GB2460781B (en) 2007-03-28 2012-01-25 Alimentary Health Ltd Probiotic bifidobacterium strains
WO2008134450A2 (fr) 2007-04-24 2008-11-06 Kemin Industries, Inc. Activité antibactérienne et antifongique à spectre large de lactobacillus johnsonii d115
EP1997499A1 (fr) 2007-05-31 2008-12-03 Puleva Biotech, S.A. Microorganismes de lait maternel, compositions les contenant et leur utilisation pour le traitement de métastase
EP1997905A1 (fr) 2007-06-01 2008-12-03 Friesland Brands B.V. Amplification d'acide nucléique
EP1997907A1 (fr) 2007-06-01 2008-12-03 Friesland Brands B.V. Bifidobactéries
EP1997906A1 (fr) 2007-06-01 2008-12-03 Friesland Brands B.V. Lactobacillus
WO2008153377A1 (fr) 2007-06-15 2008-12-18 N.V. Nutricia Nutrition avec une bifidobactérie non viable et un oligosaccharide non digestible
EP2522358B1 (fr) 2007-06-27 2016-11-09 Laboratorios Ordesa, S.l. Peptides contres les infections par le rotavirus
US20110027348A1 (en) 2007-08-27 2011-02-03 Janos Feher Composition and method inhibiting inflammation
WO2009030254A1 (fr) 2007-09-04 2009-03-12 Curevac Gmbh Complexes d'arn et de peptides cationiques pour transfection et immunostimulation
US20100284979A1 (en) 2007-10-01 2010-11-11 University College Cork, National University Of Ireland, Cork Modulation of Tissue Fatty Acid Composition of a Host by Human Gut Bacteria
US8658153B2 (en) 2007-10-20 2014-02-25 Universite De Liege Bifidobacterial species
CA2740434C (fr) 2007-10-26 2017-11-07 Brenda E. Moore Compositions probiotiques et procedes pour induire et maintenir une perte de poids
WO2009059284A2 (fr) 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Compositions de polysaccharides non anticoagulants
EP2065048A1 (fr) 2007-11-30 2009-06-03 Institut Pasteur Utilisation d'une souche de L. casei pour la préparation d'une composition pour l'inhibition de l'activation de mastocytes
CN101969966B (zh) 2007-12-07 2013-05-08 努特里希亚公司 用于尘螨变态反应的双歧杆菌
WO2009079564A2 (fr) 2007-12-17 2009-06-25 Emory University Compositions immunogènes et leurs procédés d'utilisation
ES2343499B1 (es) 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
BRPI0908348A2 (pt) 2008-02-06 2015-07-28 Procter & Gamble Métodos e kits de composições para acentuar a resposta imunológica a uma condição respiratória
EP2103226A1 (fr) 2008-03-18 2009-09-23 Friesland Brands B.V. Produit alimentaire probiotique de longue durée
ES2594102T3 (es) 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
WO2009138220A1 (fr) 2008-05-13 2009-11-19 Glycotope Gmbh Procédé de fermentation
MX2008006546A (es) 2008-05-21 2009-11-23 Sigma Alimentos Sa De Cv Bifidobacteria productora de ácido fólico, composición alimenticia y uso de la bifidobacteria.
CN101590081A (zh) 2008-05-28 2009-12-02 青岛东海药业有限公司 凸腹真杆菌和两形真杆菌制剂及其应用
CN102940652B (zh) 2008-05-28 2015-03-25 青岛东海药业有限公司 两形真杆菌制剂及其应用
US8586029B2 (en) 2008-06-04 2013-11-19 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
EP2133088A3 (fr) 2008-06-09 2010-01-27 Nestec S.A. Rooibos et inflammation
WO2009151315A1 (fr) 2008-06-13 2009-12-17 N.V. Nutricia Composition nutritionnelle pour nourrissons nés par césarienne
WO2009154463A2 (fr) 2008-06-20 2009-12-23 Stichting Top Institute Food And Nutrition Le butyrate comme médicament permettant d'améliorer la perception viscérale chez l'homme
EP2138186A1 (fr) 2008-06-24 2009-12-30 Nestec S.A. Probiotiques, IgA de sécrétion et inflammation
WO2010002241A1 (fr) 2008-06-30 2010-01-07 N.V. Nutricia Composition nutritive pour bébés nés par césarienne
KR101017448B1 (ko) 2008-09-18 2011-02-23 주식회사한국야쿠르트 대장의 건강 증진 효능을 갖는 비피도박테리움 롱검 에이취와이8004 및 이를 유효성분으로 함유하는 제품
US20100074870A1 (en) 2008-09-19 2010-03-25 Bristol-Myers Squibb Company Probiotic infant products
US8137718B2 (en) 2008-09-19 2012-03-20 Mead Johnson Nutrition Company Probiotic infant products
KR101057357B1 (ko) 2008-09-22 2011-08-17 광주과학기술원 유산균 및 콜라겐을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물
US9603876B2 (en) 2008-09-25 2017-03-28 New York University Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
WO2010037408A1 (fr) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprenant un arnm complexé et un arnm nu pour déclencher ou augmenter une réponse immunostimulante chez un mammifère et utilisations de ladite composition
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
JP2012510800A (ja) 2008-12-05 2012-05-17 ネステク ソシエテ アノニム 低出生体重児において使用するための組成物
US20120107279A1 (en) 2008-12-19 2012-05-03 Nestec S.A. Prevention and treatment of rotavirus diarrhoea
IT1392672B1 (it) 2009-01-12 2012-03-16 Wyeth Consumer Healthcare S P A Composizioni comprendenti componenti probiotici e prebiotici e sali minerali, con lactoferrina
EP2772269A3 (fr) 2009-03-05 2015-01-14 Abbvie Inc. Protéines se liant à un IL-17
JP5710876B2 (ja) 2009-03-26 2015-04-30 クロスフィールドバイオ株式会社 新規ビフィドバクテリウム属微生物およびその利用
WO2010129707A1 (fr) * 2009-05-05 2010-11-11 Amgen Inc. Etanercept en combinaison avec des glucocorticoïdes à utiliser dans le cadre du traitement du psoriasis
EP2427499A1 (fr) 2009-05-07 2012-03-14 Tate&Lyle Ingredients France SAS Compositions et procédés de fabrication d'alpha-(1,6)-oligodextranes alpha-(1,2)-ramifiés
EP2429538B1 (fr) 2009-05-11 2015-10-21 Nestec S.A. Bifidobacterium longum ncc2705 ne se répliquant pas et troubles immunitaires
EP2251022A1 (fr) 2009-05-11 2010-11-17 Nestec S.A. Micro-organismes sans réplication, et leur effet d'augmentation immunitaire
EP2251020A1 (fr) 2009-05-11 2010-11-17 Nestec S.A. Traitement haute température de courte durée qui génère des préparations microbiennes avec des profils anti-inflammatoires
KR20100128168A (ko) 2009-05-27 2010-12-07 중앙대학교 산학협력단 공액 리놀레산 생산능이 우수한 신규한 균주
US20100311686A1 (en) 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
WO2010143940A1 (fr) 2009-06-12 2010-12-16 N.V. Nutricia Mélange synergique de bêta-galacto-oligosaccharides avec des liaisons bêta-1,3 et bêta-1,4/1,6
EP2443259A4 (fr) 2009-06-16 2012-10-10 Univ Columbia Biomarqueurs associés à l'autisme et utilisations de ces derniers
WO2011005756A1 (fr) 2009-07-06 2011-01-13 Puretech Ventures, Llc Administration d'agents ciblés contre des niches de microbiote
AU2010274941A1 (en) 2009-07-24 2012-02-09 Southwest Regional Pcr, Llc Universal microbial diagnosis, detection, quantification, and specimen-targeted therapy
ES2664724T3 (es) 2009-08-18 2018-04-23 Nestec S.A. Composición nutricional que comprende cepas de Bifidobacterium longum y que reduce los síntomas de alergia alimentaria, especialmente en lactantes y niños
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011036539A1 (fr) 2009-09-23 2011-03-31 Borody Thomas J Thérapie pour infections entériques
EP2308498A1 (fr) 2009-09-30 2011-04-13 Nestec S.A. Administration de bifidobacterium rapide au cours de l'enfance pour empêcher une inflammation postérieure au cours de la vie
US20120238468A1 (en) 2009-10-05 2012-09-20 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
WO2011044208A1 (fr) 2009-10-06 2011-04-14 Scott Dorfner Formulations antibiotiques exerçant des effets secondaires gastro-intestinaux réduits
ES2595444T3 (es) 2009-11-11 2016-12-30 Alimentary Health Limited Cepa de Bifidobacterium probiótica
WO2011075138A1 (fr) 2009-12-18 2011-06-23 Hill's Pet Nutrition, Inc. Compositions alimentaires pour animaux de compagnie comprenant des probiotiques et procédés de fabrication et d'utilisation de celles-ci
US20150104418A1 (en) 2014-12-18 2015-04-16 Microbios, Inc. Bacterial composition
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
NL2004200C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides in weight management.
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
JP5737646B2 (ja) 2010-03-24 2015-06-17 森下仁丹株式会社 抗アレルギー剤
WO2011121379A1 (fr) 2010-03-30 2011-10-06 Assistance Publique - Hopitaux De Paris Utilisation de bifidobactéries pour prévenir les allergies chez les enfants nourris au sein
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011149335A1 (fr) 2010-05-25 2011-12-01 N.V. Nutricia Composition nutritionnelle d'empreinte immunitaire
KR20130086155A (ko) 2010-06-01 2013-07-31 무어 리서치 엔터프라이지스 엘엘씨 박테로이데스로부터의 세포 성분, 그의 조성물, 및 박테로이데스 또는 그의 세포 성분을 이용하는 치료 방법
WO2011151941A1 (fr) 2010-06-04 2011-12-08 国立大学法人東京大学 Composition présentant une activité d'induction de la prolifération ou de l'accumulation de cellule t régulatrice
TWI417054B (zh) 2010-06-15 2013-12-01 Jen Shine Biotechnology Co Ltd 新穎糞腸球菌ｌｊｓ－０１及其益生用途
EP2397145A1 (fr) 2010-06-18 2011-12-21 Nestec S.A. L. johnsonii La1, B. longum NCC2705 et troubles immunitaires
FR2962045B1 (fr) 2010-07-05 2012-08-17 Bifinove Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe moleculaire pour prevenir et traiter les rhumatismes inflammatoires
TWI401086B (zh) 2010-07-20 2013-07-11 Univ China Medical 胚芽乳酸桿菌及其用途
EP3235506B1 (fr) 2010-07-26 2023-12-06 Qu Biologics Inc. Compositions immunogènes anti-inflammatoires
US9308226B2 (en) 2010-08-04 2016-04-12 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
KR101250463B1 (ko) 2010-10-12 2013-04-15 대한민국 신생아 분변에서 분리한 내산소성 비피도박테리움 롱검 비피더스 유산균 및 이를 이용한 프로바이오틱 조성물
EP2633074A1 (fr) 2010-10-27 2013-09-04 Quantibact A/s Capture d'adn et d'arn cibles par des sondes comprenant des molécules intercalaires
CN102031235B (zh) 2010-11-09 2012-07-25 中国农业大学 一种粪肠球菌anse228及其应用
EP2455092A1 (fr) 2010-11-11 2012-05-23 Nestec S.A. Protection de micro-organismes probiotiques sans réplication contre les infections des voies respiratoires supérieures
US20120128644A1 (en) 2010-11-24 2012-05-24 Oragenics, Inc. Use of Bacteria to Treat and Prevent Respiratory Infections
CN102093967B (zh) 2010-12-02 2013-01-30 中国农业科学院特产研究所 一株水貂源屎肠球菌及其应用
ES2389547B1 (es) 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
US9376473B2 (en) 2011-01-10 2016-06-28 Cleveland Biolabs, Inc. Use of Toll-Like Receptor agonist for treating cancer
PT2481299T (pt) 2011-01-31 2017-03-08 Synformulas Gmbh Estirpes de bifidobacterium bifidum para aplicação em doenças gastrointestinais
JP5840368B2 (ja) 2011-02-02 2016-01-06 カルピス株式会社 関節炎予防改善用物質
WO2012108830A1 (fr) 2011-02-09 2012-08-16 Lavivo Ab Compositions symbiotiques pour la restauration et la reconstitution du microbiote intestinal
EP4129312A1 (fr) 2011-03-09 2023-02-08 Regents Of The University Of Minnesota Compositions et procédés de transplantation de microbiote du côlon
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
WO2012140636A1 (fr) 2011-04-11 2012-10-18 Alimentary Health Limited Formulation probiotique
WO2012142605A1 (fr) 2011-04-15 2012-10-18 Samaritan Health Services Agent de déploiement de recolonisation rapide
JP2014512388A (ja) 2011-04-20 2014-05-22 マイコ・バイオ，インコーポレーテッド 免疫反応を増進するための組成物および方法
US9567361B2 (en) 2011-05-13 2017-02-14 Glycosyn LLC Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
WO2012162335A2 (fr) * 2011-05-23 2012-11-29 Washington State University Research Foundation Utilisation d'agents de stabilisation de pigment photosynthétique pour réguler le mûrissement et la qualité de fruits et de légumes
KR20120133133A (ko) 2011-05-30 2012-12-10 한국 한의학 연구원 생약 추출물 또는 이의 유산균 발효물을 포함하는 호흡기 질환의 예방 또는 치료용 조성물
US20140171339A1 (en) 2011-06-06 2014-06-19 The University Of North Carolina At Chapel Hill Methods and kits for detecting adenomas, colorectal cancer, and uses thereof
GB201110095D0 (en) 2011-06-15 2011-07-27 Danisco Method of treatment
JP2013005759A (ja) 2011-06-24 2013-01-10 Kyodo Milk Industry Co Ltd マウス腸内菌叢の推測方法
WO2013005836A1 (fr) 2011-07-07 2013-01-10 長岡香料株式会社 Inhibiteur d'absorption de fructose
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
US20130017999A1 (en) 2011-07-14 2013-01-17 Marc Fremont Methods and Compositions for Evaluating and/or Treating Chronic Immune Diseases
US20130022575A1 (en) 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora
CN102304483A (zh) 2011-08-12 2012-01-04 北京金泰得生物科技股份有限公司 一株饲用屎肠球菌及其应用
KR101261872B1 (ko) 2011-08-23 2013-05-14 대한민국 (식품의약품안전처장) 장내 미생물 효소복합체 및 이의 제조방법
CA2848757C (fr) 2011-09-14 2021-11-09 University Of Guelph Complements de milieu et procedes de culture de microorganismes anaerobies gastro-intestinaux humains
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
LT2750682T (lt) 2011-10-11 2016-10-10 Achim Biotherapeutics Ab Kompozicija, apimanti anaerobiškai auginamą žmogaus žarnyno mikroflorą
CN103082292B (zh) 2011-11-02 2015-03-04 深圳华大基因研究院 罗斯氏菌(Roseburia)在治疗和预防肥胖相关疾病中的应用
CN102373172B (zh) 2011-11-03 2013-03-20 北京龙科方舟生物工程技术有限公司 一株屎肠球菌及其应用
CN104160014A (zh) 2011-12-01 2014-11-19 国立大学法人东京大学 诱导调节性t细胞的增殖或积累的人源细菌
ES2408279B1 (es) 2011-12-15 2014-09-09 Universidad De Las Palmas De Gran Canaria Bacteria acido láctica probiótica
ITBG20120010A1 (it) 2012-02-24 2013-08-25 Milano Politecnico Dispositivo per l'addestramento chirurgico
ITMI20120471A1 (it) 2012-03-26 2013-09-27 Giovanni Mogna Composizione a base di ceppi di batteri bifidobacterium longum in grado di aiutare il prolungamento della vita
JP5792105B2 (ja) 2012-03-27 2015-10-07 森永乳業株式会社 ラクト−ｎ−ビオースｉの製造方法
EP2832859B1 (fr) 2012-03-30 2018-07-25 Ajinomoto Co., Inc. Bactérie induisant le diabète
WO2013154826A2 (fr) 2012-04-11 2013-10-17 Nestec Sa Procédés de diagnostic de diarrhée imminente
MX2014012362A (es) 2012-04-13 2015-05-07 Trustees Boston College Composición prebiótica y métodos de uso.
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
DK2850202T3 (da) 2012-05-18 2020-05-18 Genome Res Ltd Fremgangsmåder og grupper
ES2436251B1 (es) 2012-05-25 2014-10-08 Consejo Superior De Investigaciones Científicas (Csic) Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas.
JP6436580B2 (ja) 2012-06-04 2018-12-12 ガウラブ アグラーワル， クローン病および関連する状態および感染症を処置するための組成物および方法
CN102743420A (zh) 2012-06-06 2012-10-24 上海交通大学 改善肠道菌群结构的方法及应用
WO2014001368A1 (fr) 2012-06-25 2014-01-03 Orega Biotech Anticorps antagonistes de l'il-17
EP2879523B1 (fr) 2012-07-31 2016-11-16 Nestec S.A. Composition nutritionnelle pour promouvoir la santé musculo-squelettique chez les patients atteints de la maladie intestinale inflammatoire (ibd)
WO2014019271A1 (fr) 2012-08-01 2014-02-06 Bgi Shenzhen Biomarqueurs pour le diabète et utilisations correspondantes
WO2014032108A1 (fr) 2012-08-29 2014-03-06 Borody Thomas J Compositions de laxatif et méthodes de traitement de la constipation et des maladies et troubles gastro-intestinaux associés
CA2881656C (fr) 2012-08-29 2023-07-11 California Institute Of Technology Diagnostic et traitement du trouble du spectre autistique
WO2014043593A2 (fr) 2012-09-13 2014-03-20 Massachusetts Institute Of Technology Profils d'administration de médicaments programmables de bactéries ciblées par une tumeur
KR101473058B1 (ko) 2012-09-19 2014-12-16 주식회사 쎌바이오텍 과민성 대장 증후군 예방 또는 치료용 조성물
CN103652322B (zh) 2012-09-21 2016-02-10 临沂思科生物科技有限公司 一种含乳酸菌的复合益生菌饲料添加剂的制备方法
WO2014053608A1 (fr) 2012-10-03 2014-04-10 Metabogen Ab Identification d'une personne ayant un risque d'athérosclérose et de maladies associées par le microbiome intestinal de la personne et prévention de telles maladies
FR2997091B1 (fr) 2012-10-22 2016-05-06 Fond Mediterranee Infection Utilisation d'un compose antioxydant pour la culture de bacteries sensibles a la tension en oxygene
WO2014070225A1 (fr) 2012-10-30 2014-05-08 Deerland Enzymes, Inc. Compositions prébiotiques comprenant un ou plusieurs types de bactériophage
US20150290140A1 (en) 2012-10-30 2015-10-15 Nestec S.A. Compositions comprising microparticles and probiotics to deliver a synergistic immune effect
EP2914135A1 (fr) 2012-11-01 2015-09-09 Rijksuniversiteit Groningen Procédés et compositions pour la stimulation de bactéries bénéfiques dans le tractus gastro-intestinal
WO2014075745A1 (fr) 2012-11-19 2014-05-22 Université Catholique de Louvain Utilisation d'akkermansia pour le traitement de troubles métaboliques
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2014082050A1 (fr) * 2012-11-23 2014-05-30 Seres Health, Inc. Compositions bactériennes synergiques et leurs procédés de production et d'utilisation
CN104918624A (zh) 2012-11-26 2015-09-16 托马斯·朱利叶斯·波洛迪 恢复排泄物微生物群的组合物及其制造和使用方法
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
BR112015013784A2 (pt) 2012-12-12 2017-07-11 Massachusetts Inst Technology aplicação, manipulação e otimização de sistemas, métodos e composições para manipulação de sequência e aplicações terapêuticas
JP6552965B2 (ja) 2012-12-12 2019-07-31 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための改善された系、方法および酵素組成物のエンジニアリングおよび最適化
US20140193464A1 (en) 2013-01-08 2014-07-10 Imagilin Technology, Llc Effects of probiotics on humans and animals under environmental or biological changes
EP3904502A3 (fr) 2013-02-04 2022-02-23 Seres Therapeutics, Inc. Compositions et procédés
EP3587558A3 (fr) 2013-02-04 2020-03-04 Seres Therapeutics, Inc. Procédé de chargement d'un tractus gastro-intestinal
CA2940226A1 (fr) 2013-02-22 2014-08-28 The Regents Of The University Of California Compositions et procedes de promotion de la croissance de microbes benefiques pour traiter ou prevenir une maladie ou prolonger la vie
MX2015011700A (es) 2013-03-05 2016-07-20 Univ Groningen Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion.
EP2971148A4 (fr) 2013-03-14 2016-08-17 Seres Therapeutics Inc Procédés de détection de pathogènes et d'enrichissement à partir de matériaux et de compositions
WO2014152338A1 (fr) 2013-03-14 2014-09-25 Kabadi Mohan Administration ciblée d'organismes probiotiques et/ou d'agents thérapeutiques dans le tractus gastro-intestinal
US9669059B2 (en) 2013-03-15 2017-06-06 University Of Florida Research Foundation, Incorporated Butyrogenic bacteria as probiotics to treat clostridium difficile
EP2967077A4 (fr) 2013-03-15 2016-09-14 Seres Therapeutics Inc Compositions microbiennes et procédés associés basés sur un réseau
CN103156888A (zh) 2013-03-18 2013-06-19 广州知光生物科技有限公司 脆弱拟杆菌在制备治疗炎症性肠病组合物中的应用
CN103142656A (zh) 2013-03-18 2013-06-12 广州知光生物科技有限公司 脆弱拟杆菌在制备防治结肠癌组合物中的应用
CN103146620A (zh) 2013-03-25 2013-06-12 广州知光生物科技有限公司 具有益生菌特性的脆弱拟杆菌
JP2014196260A (ja) 2013-03-29 2014-10-16 公立大学法人奈良県立医科大学 慢性閉塞性肺疾患の予防又は治療用組成物
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
JP2016521284A (ja) 2013-05-10 2016-07-21 カリフォルニア インスティチュート オブ テクノロジー 大腸ガンのプロバイオティクスによる防止および処置
AU2014275025B2 (en) 2013-06-05 2016-12-01 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US20160120915A1 (en) 2013-06-10 2016-05-05 New York University Methods for manipulating immune responses by altering microbiota
WO2014200334A1 (fr) 2013-06-14 2014-12-18 N.V. Nutricia Composition synbiotique pour le traitement d'infections chez des patients allergiques
WO2015003001A1 (fr) 2013-07-01 2015-01-08 The Washington University Procédés pour identifier des compléments qui augmentent la colonisation intestinale par une espèce bactérienne isolée, et compositions dérivées
DK3016511T3 (da) 2013-07-02 2020-01-13 Austrianova Singapore Pte Ltd En fremgangsmåde til at frysetørre indkapslede celler, sammensætninger egnet til at fryse indkapslede celler og anvendelse af sådanne sammensætninger
WO2015003305A1 (fr) 2013-07-08 2015-01-15 吉瑞高新科技股份有限公司 Étui de cigarette électronique
US9764019B2 (en) 2013-07-09 2017-09-19 Vedanta Biosciences, Inc. Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
CN105407728A (zh) 2013-07-21 2016-03-16 霍勒拜欧姆公司 用于微生物组表征、监测和治疗的方法和系统
EP3027058B1 (fr) 2013-07-31 2020-07-15 Incredible Foods, Inc. Compositions d'aliment fonctionnel enrobé
WO2015021936A1 (fr) 2013-08-16 2015-02-19 The University Of Hong Kong Méthode et compositions de traitement d'un cancer à l'aide d'une référence croisée de probiotiques à une application associée
CN103509741B (zh) 2013-08-22 2015-02-18 河北农业大学 布劳特菌auh-jld56及其在牛蒡苷元转化中的应用
WO2015038731A1 (fr) 2013-09-12 2015-03-19 The Johns Hopkins University Formation d'un biofilm pour déterminer le risque de cancer du côlon
RU2016116954A (ru) 2013-10-18 2017-11-23 ИнноваЧайлдфуд АБ Сбалансированный по пищевой ценности комбинированный пищевой продукт для детей раннего возраста и маленьких детей и способ изготовления указанного продукта
PL229020B1 (pl) 2013-11-13 2018-05-30 Inst Biotechnologii Surowic I Szczepionek Biomed Spolka Akcyjna Nowy szczep Bifidobacterium breve
AU2014352643A1 (en) 2013-11-25 2016-06-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2015095241A2 (fr) 2013-12-16 2015-06-25 Seres Health, Inc. Compositions bactériennes et leurs méthodes d'utilisation pour traiter des troubles du système immunitaire
CN103981115B (zh) 2013-12-24 2018-10-26 北京大伟嘉生物技术股份有限公司 一株高抗逆性屎肠球菌及其应用
CN103981117B (zh) 2013-12-24 2018-10-26 北京大伟嘉生物技术股份有限公司 一株高抗逆性屎肠球菌及其培养方法和应用
CN103820363B (zh) 2014-01-27 2016-02-24 福建省农业科学院生物技术研究所 一种屎肠球菌菌粉的制备与应用
CN103865846B (zh) 2014-02-27 2016-03-30 扬州绿保生物科技有限公司 一种屎肠球菌及其制备方法
CN103849590B (zh) 2014-03-25 2016-07-06 上海交通大学 一株耐酸短双歧杆菌BB8dpH及其应用
KR101683474B1 (ko) 2014-03-26 2016-12-08 주식회사 쎌바이오텍 과민성 대장 증후군 예방 또는 치료용 조성물
US9783858B2 (en) 2014-04-02 2017-10-10 Northwestern University Altered microbiome of chronic pelvic pain
KR101583546B1 (ko) 2014-04-09 2016-01-11 국립암센터 유전자 다형성을 이용한 소라페닙 치료에 대한 반응성 예측방법
US20150374760A1 (en) 2014-04-09 2015-12-31 Jose U. Scher Methods for treating psoriasis and psoriatic arthritis
MX2016013247A (es) 2014-04-10 2017-05-03 Riken Composiciones y metodos para induccion de celulas th17.
CN104195075B (zh) 2014-08-14 2017-04-19 生合生物科技股份有限公司 一种屎肠球菌ef08及包含它的饲料添加物和饲料
WO2015168534A1 (fr) 2014-05-02 2015-11-05 Novogy, Inc. Traitement thérapeutique de déséquilibres microbiens gastro-intestinaux par déplacement de microbes compétitif
KR102312186B1 (ko) 2014-05-08 2021-10-14 판옵테스 파르마 게스.엠.베.하. 안 질환 및 장애 치료용 화합물
WO2016019506A1 (fr) 2014-08-05 2016-02-11 BGI Shenzhen Co.,Limited Utilisation d'eubactérie dans la prévention et le traitement de maladies liées à un cancer colorectal
US10925953B2 (en) 2014-08-28 2021-02-23 Yale University Compositions and methods for treating an inflammatory disease or disorder
US20160058808A1 (en) 2014-09-03 2016-03-03 California Institute Of Technology Microbe-based modulation of serotonin biosynthesis
CN104546934B (zh) * 2014-09-30 2019-04-09 深圳华大基因科技有限公司 粪副拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546942A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 多氏拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546935A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 多形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546940A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 平常拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546933A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 粪拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546932A (zh) 2014-09-30 2015-04-29 深圳华大基因科技有限公司 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
WO2016057671A1 (fr) 2014-10-07 2016-04-14 University Of Virginia Patent Foundation Compositions et procédés pour la prévention et le traitement d'infection
AU2015335601A1 (en) 2014-10-24 2017-06-01 Evolve Biosystems Inc. Activated bifidobacteria and methods of use thereof
EP3998074A1 (fr) 2014-10-30 2022-05-18 California Institute of Technology Compositions et procédés comprenant des bactéries pour l'amélioration du comportement dans les troubles neurodéveloppementaux
EP3212289A4 (fr) 2014-10-30 2018-05-16 California Institute of Technology Compositions et procédés comprenant des bactéries pour améliorer le comportement dans les troubles neurodéveloppementaux
JP6868562B2 (ja) 2014-10-31 2021-05-19 ペンデュラム セラピューティクス， インコーポレイテッド 障害の微生物的処置および診断に関する方法および組成物
CN104435000A (zh) 2014-11-12 2015-03-25 江南大学 乳酸菌对支气管哮喘治疗中的应用
EP3223835A4 (fr) 2014-11-25 2018-10-24 Memorial Sloan-Kettering Cancer Center Microbiote intestinal et gvh (réaction du greffon contre l'hôte)
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
WO2016102951A1 (fr) 2014-12-23 2016-06-30 4D Pharma Research Limited Polypeptide pirin et modulation immunitaire
SI3065748T1 (en) 2014-12-23 2018-05-31 4D Pharma Research Limited Severe bacteroid tethethioomycron and its use in reducing inflammation
CN104560820B (zh) 2014-12-30 2017-10-20 杭州师范大学 屎肠球菌kq2.6及应用
CA2974510A1 (fr) 2015-01-23 2016-07-28 Temple University-Of The Commonwealth System Of Higher Education Utilisation d'acides gras a chaine courte dans la prevention du cancer
CN105982919A (zh) 2015-02-26 2016-10-05 王汉成 生物减速剂抗癌技术
WO2016139217A1 (fr) 2015-03-04 2016-09-09 Ab-Biotics, S.A. Composition comprenant un microbiote intestinal humain cultivé en conditions anaérobies
US20160271189A1 (en) 2015-03-18 2016-09-22 Whole Biome, Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
US20180078587A1 (en) 2015-03-18 2018-03-22 Trustees Of Tufts College Compositions and methods for preventing colorectal cancer
MX2017015473A (es) 2015-06-01 2018-08-15 Univ Chicago Tratamiento contra el cancer por manipulacion de la microflora comensal.
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TWI797058B (zh) 2015-06-15 2023-04-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MX2017016560A (es) 2015-06-15 2018-02-21 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas.
EA201890050A1 (ru) 2015-06-15 2018-06-29 4Д Фарма Рисёрч Лимитед Композиции, содержащие бактериальные штаммы
CN105112333A (zh) 2015-08-31 2015-12-02 江南大学 一种具有良好肠道定殖能力的长双歧杆菌及筛选方法和应用
MD3209310T2 (ro) 2015-11-20 2018-06-30 4D Pharma Res Ltd Compoziții care conțin tulpini bacteriene
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
AU2016361583B2 (en) 2015-11-25 2021-05-13 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
TW201733601A (zh) 2016-03-04 2017-10-01 ４Ｄ製藥有限公司 包含細菌菌株之組合物
WO2017160711A1 (fr) 2016-03-14 2017-09-21 Holobiome, Inc. Modulation du microbiome intestinal pour traiter les troubles mentaux ou les maladies du système nerveux central
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018112363A1 (fr) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Méthodes de traitement du cancer à l'aide de parabacteroides
WO2018112365A2 (fr) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Procédés de traitement du cancer colorectal et d'un mélanome en utilisant parabacteroides goldsteinii
RU2761873C2 (ru) 2016-12-23 2021-12-13 Кэйо Юниверсити Композиции и способы для индукции cd8+ t-клеток

Also Published As

Publication number Publication date
MD3204025T2 (ro) 2020-02-29
KR20180012845A (ko) 2018-02-06
DK3204025T3 (da) 2019-11-25
CN108738311A (zh) 2018-11-02
IL255783B2 (en) 2023-06-01
SI3369425T1 (sl) 2021-03-31
TWI782682B (zh) 2022-11-01
SI3549592T1 (sl) 2020-10-30
PT3369425T (pt) 2021-03-08
JP2018502551A (ja) 2018-02-01
AU2016278069B2 (en) 2020-07-09
BR112017025003A2 (pt) 2018-08-07
US20200138874A1 (en) 2020-05-07
RS61538B1 (sr) 2021-04-29
LT3204025T (lt) 2019-12-10
CA2988686A1 (fr) 2016-12-22
IL255783A (en) 2018-01-31
EP3204025B1 (fr) 2019-09-11
HUE052737T2 (hu) 2021-05-28
MX2017016564A (es) 2018-02-21
US20230310517A1 (en) 2023-10-05
WO2016203220A1 (fr) 2016-12-22
JP2018199695A (ja) 2018-12-20
MD3549592T2 (ro) 2020-07-31
SG10201912322PA (en) 2020-02-27
EA201890049A1 (ru) 2018-06-29
EP3549592B1 (fr) 2020-02-12
EP3884953A1 (fr) 2021-09-29
DK3369425T3 (da) 2021-03-01
AU2020241605A1 (en) 2020-10-29
EP3549592A1 (fr) 2019-10-09
TWI739746B (zh) 2021-09-21
CN108738311B (zh) 2020-11-03
HRP20200702T1 (hr) 2020-07-24
ES2758679T3 (es) 2020-05-06
PL3204025T3 (pl) 2020-02-28
MD3369425T2 (ro) 2021-07-31
PL3549592T3 (pl) 2020-11-16
CO2017013231A2 (es) 2018-03-28
ME03584B (fr) 2020-07-20
MA41060A (fr) 2017-08-15
ES2863913T3 (es) 2021-10-13
EP3369425A1 (fr) 2018-09-05
EP3204025A1 (fr) 2017-08-16
PE20180266A1 (es) 2018-02-06
LT3549592T (lt) 2020-05-25
RS59558B1 (sr) 2019-12-31
AU2016278069A1 (en) 2017-12-14
LT3369425T (lt) 2021-04-12
EP3369425B1 (fr) 2021-01-27
CL2017003191A1 (es) 2018-06-22
PT3549592T (pt) 2020-05-18
CN112370468A (zh) 2021-02-19
HRP20210246T1 (hr) 2021-05-28
US11433106B2 (en) 2022-09-06
CA2988686C (fr) 2023-01-24
US20170354695A1 (en) 2017-12-14
ES2787523T3 (es) 2020-10-16
JP6389950B2 (ja) 2018-09-12
SG10201912321RA (en) 2020-02-27
DK3549592T3 (da) 2020-04-20
TW202200173A (zh) 2022-01-01
CY1124013T1 (el) 2022-05-27
CA3182899A1 (fr) 2016-12-22
US20180344780A1 (en) 2018-12-06
HUE046221T2 (hu) 2020-02-28
ME03784B (fr) 2021-04-20
PT3204025T (pt) 2019-12-16
CY1123196T1 (el) 2021-10-29
CY1122467T1 (el) 2021-01-27
HRP20192057T1 (hr) 2020-02-21
PL3369425T3 (pl) 2021-06-28
ZA201707774B (en) 2018-11-28
US10493112B2 (en) 2019-12-03
TW201709918A (zh) 2017-03-16
HUE048823T2 (hu) 2020-08-28
RS60245B1 (sr) 2020-06-30
SI3204025T1 (sl) 2020-02-28

Similar Documents

Publication Publication Date Title
MA41060B1 (fr) Compositions comprenant des souches bactériennes
MA55434A (fr) Compositions comprenant des souches bactériennes
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MA41010B1 (fr) Compositions comprenant des souches bactériennes
MA42471B1 (fr) Compositions comprenant des souches bactériennes
MA44322A (fr) Compositions comprenant des souches bactériennes
MA41013A (fr) Compositions comprenant des souches bactériennes
MA53937B1 (fr) Compositions comprenant des souches bactériennes
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
MA42560A (fr) Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
MA49373B1 (fr) Compositions comprenant des souches bactériennes
MA41059B1 (fr) Compositions comprenant des souches bactériennes
MA41104A (fr) Compositions comprenant des souches bactériennes
MA50273B1 (fr) Compositions comprenant des souches bactériennes
MA46980B1 (fr) Compositions comprenant des souches bactériennes
MA49300A (fr) Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale